Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_1
5
50%

Phase Distribution

5

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
5(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(7)
Terminated(3)

Detailed Status

Completed7
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
70.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (50.0%)
Phase 25 (50.0%)

Trials by Status

completed770%
terminated330%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00358982
completedphase_2

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086
terminatedphase_2

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

NCT00374296
completedphase_1

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

NCT00372437
completedphase_1

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

NCT00324220
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00358982Phase 2

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Terminated
NCT00359086Phase 2

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Completed
NCT00374296Phase 2

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Terminated
NCT00372437Phase 1

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Completed
NCT00324220Phase 1

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Completed
NCT00431873Phase 2

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Completed
NCT00666497Phase 2

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated
NCT00324129Phase 1

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Completed
NCT00323934Phase 1

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Completed
NCT00324194Phase 1

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10